KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.

Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kågedal, Angelica L Quartino, Sandhya Girish, Chunze Li, Whitney P Kirschbrown

Cancer Chemother Pharmacol 88(3) 499-512

PMID34106303
PMCIDPMC8187458
DOI10.1007/s00280-021-04296-0
发表日期2021-06-09
入排依据:The record describes a Phase III randomized trial in HER2-positive early breast cancer with a drug intervention (pertuzumab and trastuzumab). However, the primary analysis is pharmacokinetic and exposure-response (safety and pathologic complete response rate), which are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.). The study lacks a primary or key secondary time-to-event endpoint.
摘要

摘要

PURPOSE: To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] versus intravenous pertuzumab plus trastuzumab); derive individual pertuzumab exposures in the PH FDC SC arm for subsequent pertuzumab exposure-response (ER) analyses; compare observed trastuzumab PK with predicted exposures from a previous SC trastuzumab model; assess whether pertuzumab affects trastuzumab PK; evaluate pertuzumab exposure-efficacy and -safety relationships and support the approved SC dosing regimen. METHODS: Population pharmacokinetic modeling and simulations were used to describe the data. Standard goodness-of-fit diagnostics and prediction-corrected visual predictive checks were used for model performance assessment. Covariates were included from previously reported models. ER analysis was conducted using logistic regression. RESULTS: SC pertuzumab PK was described adequately by a two-compartment model with first-order absorption; significant covariates included in the final model were albumin, lean body weight, and Asian region; however, these appeared not to be clinically relevant. Trastuzumab concentrations were described adequately by the previous model; there was no evidence of a pertuzumab effect on trastuzumab PK as part of PH FDC SC and higher model-predicted pertuzumab exposure was not associated with differences in pathologic complete response rate or an increased probability of selected grade ≥ 3 adverse events of interest. CONCLUSION: The approved PH FDC SC dose [loading: 1200/600 mg pertuzumab/trastuzumab (15 mL); maintenance: 600 mg pertuzumab/trastuzumab (10 mL) and 2000 U/mL recombinant human hyaluronidase every 3 weeks] provides a positive benefit-risk profile with comparable efficacy and safety to intravenous pertuzumab plus trastuzumab.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。